Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Cullinan Oncology, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer patients open to enrollment Initial monotherapy clinical data for CLN-619 presented at ASCO 2023 Annual Meeting; initiated monotherapy expansion cohorts in endometrial and cervical cancers First patient dosed in Phase 1study of CLN-978 in relapsed/refractory B Cell non-Hodgkin lymphoma Cash and investment position of $512.1 million as of June 30, 2023 continues to provide runway into 2026 CAMBRIDGE, Mass., August 10, 2023 -- Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and an..."
05/11/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results"
03/09/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results"
08/10/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results"
08/10/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
Docs: "Cullinan Oncology Reports First Quarter 2021 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy